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The β2-adrenoceptor (β2AR) is a well-established target in asthma and a prototypical 
GPCR for biophysical studies. Solubilisation of membrane proteins has classically 
involved the use of detergents. However, the detergent environment differs from the 
native membrane environment and often destabilises membrane proteins. Use of 
amphiphilic copolymers is a promising strategy to solubilise membrane proteins within 
their native lipid environment in the complete absence of detergents. Here we show 
the isolation of the β2AR in the polymer Diisobutylene maleic acid (DIBMA). We 
demonstrate that β2AR remains functional in the DIBMA lipid particle (DIBMALP) and 
shows improved thermal stability compared to the n-Dodecyl-β-D-Maltopyranoside 
(DDM) detergent solubilised β2AR. This unique method of extracting β2AR offers 
significant advantages over previous methods routinely employed such as the 
introduction of thermostabilising mutations and the use of detergents, particularly for 













G protein coupled receptors (GPCRs) are the largest family of membrane 
proteins within the human genome and are responsible for modulating a broad range 
of hormonal, neurological and immune responses. It is well established that GPCRs 
have a large therapeutic potential. Indeed, GPCRs currently represent 34% of all US 
food and drug administration (FDA) approved drugs, with 475 drugs targeting over 100 
diverse receptors (Hauser, Attwood et al. 2017). The β2-adrenoceptor (β2AR) is a 
rhodopsin-like family GPCR (Schioth and Fredriksson 2005) and member of the 
adrenoceptor family, which signals primarily through coupling the heterotrimeric Gs 
protein. It is a well-established target for asthma and has become one of the most 
studied GPCRs with several structural (Wacker, Fenalti et al. 2010, Rasmussen, 
DeVree et al. 2011, Bang and Choi 2015) and detailed biophysical studies (Manglik, 
Kim et al. 2015, Gregorio, Masureel et al. 2017) into its activation mechanism.  
 
A prerequisite for completion of biophysical and structural studies is the 
extraction and isolation of the β2AR from its cellular environment. Classically, this has 
involved the use of detergents, in the case of the β2AR and other GPCRs, n-dodecyl-
β-D-maltopyranoside (DDM) is most often used (Munk, Mutt et al. 2019). However, it 
is well established that detergent micelles do not recapitulate the environment of the 
cell membrane and, as such, protein stability is compromised. Moreover, there is 
strong evidence that phospholipid composition affects β2AR function (Dawaliby, 
Trubbia et al. 2016). Cholesterol in particular appears associated with the β2AR in 
crystal structures (Cherezov, Rosenbaum et al. 2007), and improves β2AR stability 
(Zocher, Zhang et al. 2012) and function (Paila, Jindal et al. 2011). Multiple studies 
(Leitz, Bayburt et al. 2006, Whorton, Bokoch et al. 2007) have mimicked the native 
membrane environment and improved protein stability through reconstitution of 
membrane proteins in liposomes, amphipols or synthetic nanodiscs, however these 
all require initial use of detergents to extract the membrane protein from the 
membrane. 
 
Recently, it was discovered that styrene maleic acid (SMA) copolymer directly 
incorporates into biological membranes and self-assembles into native nanoparticles, 
known as Styrene Maleic Acid Lipid Particles (SMALPs) (Knowles, Finka et al. 2009) 
(Stroud, Hall et al. 2018), avoiding the use of detergents at all stages. This has 
provided a novel method for the solubilisation of membrane proteins with their native 
receptor associated phospholipids, although some preferential extraction of native 
lipids occurs (Barniol-Xicota and Verhelst 2021).  
 
SMA has been used to solubilise a range of membrane proteins (Dorr, 
Koorengevel et al. 2014, Gulati, Jamshad et al. 2014, Sun, Benlekbir et al. 2018) 
including GPCRs (Jamshad, Charlton et al. 2015, Bada Juarez, Munoz-Garcia et al. 
2020) for both structural and biophysical studies. Such studies either improved protein 
stability compared to detergent or have allowed extraction of membrane proteins that 
were previously unstable in detergents. There is, however, evidence that the 
conformational flexibility of GPCRs within SMALPs is restricted (Mosslehy, 
Voskoboynikova et al. 2019, Routledge, Jamshad et al. 2020) therefore differing from 
the native state of the protein. Furthermore, the high absorbance of SMA copolymer 
in the far-UV region makes optical spectroscopic studies of membrane proteins that 











An alternative to SMA is Diisobutylene maleic acid (DIBMA), a copolymer which 
was developed specifically for the extraction of membrane proteins from the intact 
bilayer (Oluwole, Danielczak et al. 2017). Compared to SMALPs, DIBMALPs are 
believed to have only a mild effect on lipid packing, be compatible with optical 
spectroscopy in the far UV range, and tolerate low millimolar concentrations of divalent 
cations (Oluwole, Danielczak et al. 2017). This makes DIBMALPs far more amenable 
for functional biophysical studies. DIBMALPs have been shown to contain lipids of the 
cell membranes using lipidomic approaches (Barniol-Xicota and Verhelst 2021). 
Despite the natural polydispersity in length of polymer molecules, DIBMALPs form a 
monodisperse in size population (Oluwole, Danielczak et al. 2017, Gulamhussein, 
Meah et al. 2019, Gulamhussein, Uddin et al. 2020). Inclusion of integral membrane 
proteins such as OmpLA and α-synuclein did not affect their size distribution (Oluwole, 
Danielczak et al. 2017, Adão, Cruz et al. 2020).   
 
In this study we demonstrate isolation of the functional β2AR from the 
mammalian cell membrane using DIBMA, with improved thermal stability compared to 




Extraction of the β2AR from membranes using DIBMA.  
 The β2AR was extracted from the membrane of mammalian (T-RexTM-293) cells 
using either 1% DDM, or 3% DIBMA (Figure 1A). Figure 1B shows a comparision of 
the solubilisation efficiency of 1% DDM and 3% DIBMA as 90±11% and 32±7% 
respectively. Figures 1C shows fluorescence size exclusion chromatography (FSEC) 
of these β2AR. Figure 1C shows a peak at 1.6-1.8mL, roughly 75kDa which 
corresponds to DDM-β2AR or DIBMALP-β2AR. Additionally, there was a higher 
molecular weight peak for the DIBMALP- β2AR and two higher molecular weight peaks 
for DDM-β2AR. These peaks are presumed to correspond to protein aggregates. 
Peaks were confirmed by in gel fluorescence (figure SF2A-B).  
 
DIBMALP-β2AR retains its pharmacology 
A time-resolved fluorescence resonance energy transfer (TR-FRET) based 
ligand binding assay was established to investigate if the β2AR remained functional 
when extracted from the HEK cell membranes into DIBMALPs. Förster resonance 
energy transfer (FRET) is the non-radiative transfer of energy from an excited donor 
fluorophore to a ground state acceptor fluorophore. Energy transfer will only occur 
when the fluorescent emission spectrum of the donor overlaps with the excitation 
spectrum of the acceptor fluorophore, and these fluorophores are within ~10nm of 
each other. In this study the SNAP tag on the N terminus of the β2AR was labelled 
with donor fluorophore terbium cryptate (Lumi4-Tb). Excitation of terbium cryptate 
using a laser allowed proximity of the β2AR to acceptor fluorophores fluorescent 
propranolol and the BIODIPY F-L cysteine dye to be quantified for ligand binding and 
thermostability assays respectively. The specific labelling of the SNAP tag meant that 
it was not necessary to purify the β2AR in these studies. TR-FRET is becoming an 
increasingly used technique for ligand binding studies (Emami-Nemini, Roux et al. 
2013). 
Figure 2 shows saturation binding experiments for the fluorescent antagonist 
S-propranolol-red-630/650 (F-propranolol) binding membrane-β2AR, DDM-β2AR and 











membrane using both DDM and using the copolymer DIBMA. These data showed 
comparable affinities for F-propranolol binding to the β2AR in membranes (pKd = 7.50 
± 0.05), DDM (pKd = 7.10 ± 0.08) and DIBMA pKd = 7.00 ± 0.13), although with slightly 
reduced affinity in DIBMA compared to membranes (P=0.02, one-way ANOVA and 
Tukey’s multiple comparison). 
 
In order to better understand if the conformational state of the receptor or its 
ability to adopt different states in DIBMALPs was affected we investigated its 
pharmacology using the full agonist isoprenaline, the antagonist propranolol and the 
inverse agonist ICI 118,551 in equilibrium competition binding assays using F-
propranolol as the tracer (Figure 3). Increasing concentrations of each competing 
ligand produced a reduction in the specific binding of F-propranolol to the 2AR in 
membranes, DDM and DIBMALPs with largely comparable pKi values (Table 1). The 
only statistically significant difference was between isoprenaline binding to the 2AR 
found in membranes versus the DDM solubilised β2AR (p=0.03) (one-way ANOVA and 
Tukey’s post hoc). The slopes of all curves were similar to 1. 
 
DIBMALP-β2AR shows improved stability 
Next, we investigated the thermostability of the DIBMALP-β2AR using a novel 
ThermoFRET assay (Figure 4, Table 2). Labelling of the SNAP tag on the N terminus 
of the receptor with Lumi4-Tb allowed thermostability to be investigated without 
purifying the receptor. β2AR unfolding was initially measured by quantifying TR-FRET 
between Lumi4-Tb and BODIPY™ FL L-Cystine that covalently reacts with cysteines 
which become exposed as the receptor unfolded (Tippett, Hoare et al. 2020). 
 
Figure 4B shows the Tm of DDM solubilised β2AR as 35.2±2.4oC. Ligand-
induced shifts in thermostability were seen when the DDM solubilised β2AR was 
incubated with F-propranolol (Tm=37.8±0.4oC, p>0.05) and cyanopindolol (Tm=41.9 
±0.1 oC, p=0.04) (one-way ANOVA and Tukey’s multiple comparison test). Figure 4A 
shows the Tm of β2AR in the membrane environment as 62.42±0.2oC. No ligand 
induced shift was observed when β2AR membranes were pre-incubated with F-
propranolol or cyanopindolol, this suggests the unfolding of the receptor itself is not 
directly measurable and perhaps that these data show the disintegration of the 
membrane itself. Figure 4C shows TR-FRET thermostability data for the DIBMALP- 
β2AR, this data did not fit a Boltzmann sigmoidal curve as the top end of the 
temperature range did not plateau. No effect on any part of the curve was observed 
with the addition of F-propranolol or cyanopindolol. Therefore, as was the case in 
membranes, the observed thermostability changes in DIBMALPs likely reflect the 
melting of the lipid particles as opposed to the receptor itself.  
 
We then investigated the thermostability of the β2AR by measuring the 
reduction in TR-FRET binding of F-propranolol over an increasing temperature range 
(Figure 4D). The resulting data suggests similar Tm values determined for the 
membrane-β2AR (60.1±0.6 oC) and DDM-β2AR (36.0±0.6 oC) to those obtained using 
BODIPY™ FL L-Cystine in the presence of F-propranolol. Unpaired two-tailed t tests 
showed no statistically significant differences between membrane-β2AR +F-
propranolol or DDM-β2AR+F-propranolol Tm values obtained using ThermoFRET Vs 












Thermostability of DIBMALP-β2AR measured by the decrease in F-propranolol 
binding gave a curve that could be fitted to a Boltzmann with a Tm value of 46.8 ± 2.1 
oC. This Tm value is statistically significant from that of membrane-β2AR (p=0.0002) 
and DDM-β2AR (p=0.0009) obtained by the same method (one-way ANOVA and 
Tukey’s multiple comparison test). Therefore, the DIBMALP-β2AR shows 
approximately 10oC improved stability over the conventional DDM-β2AR. We also 
observed differences in the slopes of DIBMALP-β2AR and DDM-β2AR thermostability 
curves obtained by this method, these were -3.2 and -2.7 respectively. Additionally, 
we investigated the thermostability of another rhodopsin-like GPCR, the adenosine 2A 
receptor (A2AR) when solubilised into a DIBMALP using fluorescent adenosine 
receptor antagonist (F-XAC) (Hello Bio, UK). Measuring the reduction in F-XAC bound 
to A2AR over an increased temperature range gave a Tm value of 44.8oC±0.7, which 
was not statistically significantly different from that of the DIBMALP-β2AR. 
 
Discussion 
The β2AR has become the prototypical GPCR for understanding GPCR 
structure and the molecular basis of signaling (Bang and Choi 2015) (Gregorio, 
Masureel et al. 2017), these studies have all required the use of detergents to extract 
the β2AR from the plasma membrane. Detergents do not recapitulate the complexity 
of the native membrane environment and are known to damage membrane proteins. 
Here, we demonstrate that the polymer DIBMA can be used to extract the β2AR from 
the plasma membrane, together with its native phospholipids, avoiding the use of 
detergents at any stage.  
 
Similarly, to (Gulamhussein, Uddin et al. 2020) we show that DIBMA can be 
used to extract GPCRs from cell membranes and that the solubilisation efficiency of 
DIBMA is lower than that of SMA or in our case the detergent DDM.  We then used 
TR-FRET ligand binding studies to show that the β2AR remained functional inside the 
DIBMALP (Figure 2-3). Ligand binding data showed comparable affinity (pKd/Ki) 
values for the β2AR binding F-propranolol, propranolol, ICI 118,551 and isoprenaline 
solubilised in DIBMA compared to membranes. Although the difference in pKd values 
for F-propranolol binding membranes-β2AR (7.5±0.05) and DIBMALP-β2AR (7.0±0.13) 
was statistically different (P=0.02), this is only a 3-fold difference and the 
pharmacological importance of this remains to be seen. There was no statistical 
difference between F-propranolol pKd values for DDM-β2AR and DIBMALP- β2AR. All 
ligand binding curves showed one phase binding and a slope of 1 indicating no co-
operativity of ligand binding.  
 
While the pKd values for different preparations of the receptor were comparable, 
the signal amplitude obtained for F-propranolol binding DIBMALP-β2AR in TR-FRET 
experiments was 3-fold lower than for membranes-β2AR. This reduction in signal 
amplitude could be due to an effect of the DIBMA polymer on the TR-FRET, for 
example fluorescence quenching. Alternatively, it could reflect that a lower fraction of 
the ligand binding capable β2AR receptors are present compared to the amount of 
Tb3+ labelled receptor molecules. However, it should be noted that the assay window 
for DDM-β2AR was higher than that of membranes whilst it would be expected that 
less β2AR is functional, suggesting that the solubilization environment can influence 
the observed signal amplitude. Whilst the concentration of β2AR used in each 











possible to account for difference in Lumi4-Tb quantum yield in the membrane, DDM 
and DIBMALP environments.  
 
It has been shown that the conformational changes of another class A GPCR, 
Rhodopsin II in response to activation by light are restricted in SMALPs (Mosslehy, 
Voskoboynikova et al. 2019). We chose to study the binding of a full agonist 
(isoprenaline), antagonist (propranolol) and inverse agonist (ICI 118,551) to be able 
to ascertain if conformational states of the β2AR differed in a membrane, DDM micelle, 
or DIBMALP environment. A substantial increase or decrease in pKi value would 
demonstrate an increase or decrease in the population of the receptors in the 
conformational state stabilized by the ligand, and therefore a difference in the 
conformational landscape of the receptor. As there was no statistically significant 
difference in pKi values between membrane-β2AR and DIBMALP-β2AR it can be 
concluded that the DIBMALP-β2AR represents the native conformational landscape of 
the β2AR. The difference in pKi value between DDM-β2AR (6.3±0.13) and membrane-
β2AR (5.5±0.2) for isoprenaline was statistically significant (p=0.03), this may indicate 
a change in the conformational state of β2AR in the DDM micelle compared to its native 
conformational state. Propranolol, ICI 118,551 and isoprenaline pKi values obtained 
in this study are in line with the previous studies that investigate the affinity of these 
compounds for the β2AR (Baker 2005) (Sykes, Parry et al. 2014). 
  
 Furthermore, we employed a ThermoFRET based thermostability assay to 
investigate the stability of the DIBMALP-β2AR compared to the DDM-β2AR. We show 
the thermostability of DIBMALP-β2AR is 10oC higher than that of the DDM-β2AR. It 
was not possible to find any thermostability data for the β2AR in synthetic nanodiscs; 
however, the only other method to show a similar (11oC) increase in thermostability 
for β2AR is that of thermostabilising mutations (Serrano-Vega and Tate 2009). Since 
these mutations also lead to a shift in the β2AR’s conformational landscape to the 
antagonist-bound and inactive form, the DIBMALP-β2AR offers a clear advantage for 
study of receptor function.  
 
 Moreover, thermostability data for DIBMALP-β2AR using F-propranolol showed 
a Tm value that was very similar to the Tm of DIBMALP-A2AR. In addition, no shift in 
thermostability was observed for DIBMALP-β2AR preincubated with F-propranolol or 
the high-affinity antagonist cyanopindolol. It therefore seems likely that this Tm value 
of ~45oC for DIBMALP-β2AR corresponds to the melting temperature of the DIBMALP. 
Interestingly, this Tm value of ~45oC is lower than that of ~50oC reported for SMALP- 
A2AR extracted from yeast membranes using a radioligand based thermostability 
assay but slightly higher that ~42oC A2AR extracted from mammalian (HEK293) 
membranes (Jamshad, Charlton et al. 2015).  The Tm of 60.2 ± 0.2oC seen for β2AR 
in membranes was also unaffected by the presence of F-propranolol and 
cyanopindolol. As this Tm of 60.2 ±0.2 oC is statistically significant from that of the 
DIBMALPs it seems likely that the Tm of ~45oC corresponds to disruption of the 
protein-lipid-polymer particles, whilst the Tm of 60.2 ±0.2oC corresponds to the melting 
or disruption of the membrane itself. We also noted a shallower slope for DIBMALP-
β2AR (-3.2) compared to DDM-β2AR (-2.7), this broader transition may reflect the more 
heterogenous nature of DIBMALPs compared to the detergent micelle.  
 
 In summary, here we show the utility of the copolymer DIBMA to solubilise the 











use of the conventional detergent DDM and has allowed us to maintain the native 
environment and ligand binding activity of the β2AR.This could therefore provide an 
improved solubilisation method for structural and biophysical studies. Moreover, we 
demonstrate this using novel TR-FRET ligand binding based methods that should 
allow for easier screening of membrane protein solubilisation conditions and anticipate 
that this approach could be applied to other GPCRs.   
 
Limititations of the study 
As discussed above, one limitation of the study is that we cannot be certain about the 
cause of the decreased signal window in the ligand binding assays for DIBMALP-β2AR 
Vs membrane-β2AR and DDM-β2AR. This could be indicative of less DIBMALP- β2AR 
being functional compared to in membranes, although there could be a number of 
other reasons such as descrease quantum yield of either donor or acceptor, as 
discussed. Furthermore, although we showed that DIBMALP- β2AR retains ligand 
binding, we have not tested other functionality of the receptor such as its ability to 
activate G proteins or recruit arrestins . Such studies would require the purification of 
















Further information and requests for resources and reagents should be directed to 




Plasmids generated in this study are available from the lead contact upon request, 
subject to the MTA with the University of Nottingham.  
 
Data and code availability 
Any additional information required to reanalyze the data reported in this paper is 
available from the lead contact upon request. 
 
Experimental model and subject details 
No human subject or animal models were used in this study. The cell lines T-RexTM-
293 cells stably expressing pcDNA4TO-TS-SNAP-β2AR or pcDNA4TO-TS-SNAP- 
A2A were used in this study. These cell lines were maintained in high glucose DMEM 
(Sigma D6429) with 10% foetal bovine serum (FBS), 5μg/μL blasticidin and 20μg/μL 
zeocin, at 37°C and 5% CO2. 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Bacterial and virus strains  




Chemicals, peptides, and recombinant proteins 
SNAP-Lumi4-Tb Cis bio SSNPTBX 
n-Dodecyl- β-D-maltopyranoside (DDM) Anatrace, OH, US D3010S 
Diisobutylene Maleic acid (DIBMA) Anatrace, OH, US BMA1011 





633/650 S-propranolol-red CellAura, UK, 
supplied by Hello 
Bio, UK  
Cat no. HB7817  
Fluorescent XAC CA200634 CellAura, UK, 
supplied by Hello 
Bio, UK  
Cat no.  
HB7814 
ICI, 118 551 hydrochloride Selleckchem, US Cat no. S8114 
1217094-53-5 
Isoprenaline hydrochloride Sigma Cat no. I5627 
CAS-51-30-9 
(s)-(-)-Propranolol hydrochloride  Tocris, UK Cat no. 0834 
CAS 4199-10-4 












BODIPYTM FL L- Cystine dye  Molecular Probes, 
US 
B20340 
NuPAGETM MOPS SDS running buffer (x20) Invitrogen NP0001 
Experimental models: Cell lines 
T-RexTM-293 cells (parent cell line) Invitrogen 
Cat.no. R71007 
Stable cell line T-RexTM-293 expressing TS-
SNAP- β2AR 
plasmid generated 
in this study 
This study 
 
Stable cell line T-RexTM-293 expressing TS-
SNAP- A2A 
plasmid generated 




CMV forward sequencing primer Genewiz, UK CGCAAATGGG
CGGTAGGCGT
G 
BGH reverse sequencing primer  Genewiz, UK TAGAAGGCACA
GTCGAGG 
Recombinant DNA 
TS-SNAP- β2AR in pcDNA4/TO This study This study, SI 
TS-SNAP- A2A in pcDNA4/TO This study This study, SI 
Software and algorithms 
GraphPad Prism 8.0.0 GraphPad 
software, CA, US 
www.graphpad.c
om 
PHERAstar v5.41. BMG, UK BMG Pherastar 
FSX platereader 
Other 





Yarra 1.8μm SEC-x300 2.5mL column  Phenomenex, CA, 
US 
00H-4743-E0-SS 
TruPageTM Precast Gels 4-20%. Sigma PCG2008 
PHERAstar ® FSX equipped with Time 
Resolved Fluorescence lasers and module, 
and TR337/665/620 and 
TR337/520/620modules  
BMG, UK PHERAstar ®  
FSX 
ProxiPlate-384 Plus PerkinElmer, MA, 
US 
6008280 
OptiPlate-384 PerkinElmer, MA, 
US 
6007290 

















Method details  
 
Molecular biology 
The construct pcDNA4TO-TwinStrep (TS)-SNAP-β2AR was generated by 
amplification of the SNAP and β2AR sequences of the pSNAPf-ADRB2 plasmid (NEB) 
and insertion into pcDNA4TO-TS using Gibson assembly (Heydenreich, Miljus et al. 
2017, Heydenreich, Miljuš et al. 2020). The construct pcDNA4TO-TS-SNAP-A2A was 
generated by amplifying the A2A receptor from the pDNA3.1 SNAP A2A construct 
described in (Comeo, Kindon et al. 2020) and inserting into pcDNA4TO-TS-SNAP 
vector using Gibson assembly. This therefore gave the construct pcDNA4TO-TS-
SNAP-A2A. Both constructs used a signal peptide based on the 5HT3A receptor to 
increase protein folding and expression.  
 
Transfection and mammalian cell culture 
pcDNA4TO-TS-SNAP-β2AR or pcDNA4TO-TS-SNAP-A2A were stably transfected into 
T-RexTM-293 cells (Invitrogen) using polyethylenimine (PEI). A mixed population 
stable line was selected by resistance to 5 µg/mL blasticidin and 20 µg/mL Zeocin. 
Stable cell lines were maintained in high glucose DMEM (Sigma D6429) with 10% 
foetal bovine serum (FBS), 5μg/μL blasticidin and 20μg/μL zeocin, at 37°C and 5% 
CO2. When ~70% confluent TS-SNAP-β2AR expression was induced with 1μg/mL 
tetracycline. Cells were left to express for 50hrs before harvesting.  
 
Labelling TS-SNAP-β2AR with Terbium cryptate or SNAP-AlexaFluor488 or 647 
Media was aspirated from T175 flasks and adherent cells washed twice at room 
temperature with Phosphate Buffered Saline (PBS). Adherent cells were labelled with 
100nM SNAP-Lumi4-Tb labelling reagent in Labmed buffer (both Cisbio, UK) for 1 hr 
at 37°C and 5% CO2, or for 30mins with SNAP-AlexaFluor 488 (NEB) in cell culture 
media. Cells were washed twice more with PBS and detached with 5mL non enzymatic 
cell dissociation solution (Sigma, UK). Cells were pelleted by centrifugation for 10 min 
at 1000xg, supernatant was removed, and cell pellets frozen at -80°C. 
 
TS-SNAP-β2AR membrane preparation  
Cell pellets were thawed on ice and resuspended in 20mL buffer B (10mM HEPES 
and 10mM EDTA, pH 7.4). Suspensions were homogenised using 6 x 1 sec pulses of 
a Polytron tissue homogeniser (Werke, Ultra-Turrax). Suspensions were centrifuged 
at 48,000xg and 4°C for 30 min, supernatant was removed and resuspended and 
centrifuged again as above. Resulting pellets were resuspended in buffer C (10mM 
HEPES and 0.1mM EDTA, pH 7.4) and frozen at -80°C. 
 
Solubilisation of TS-SNAP-β2AR using DDM or DIBMA  
Membranes were incubated with 3% DIBMA (w/v) (Anatrace, UK) in 20mM HEPES, 
10% (v/v) glycerol, and 150mM NaCl, pH 8 at room temperature or 1% DDM (w/v), 
20mM HEPES, 5% (v/v) glycerol, and 150mM NaCl, pH 8 at 4°C for 2-3 h. Samples 
were clarified by ultracentrifugation at 4°C for 1hr at 100,000xg for ligand binding 
assays and 16900xg at 4°C for 45min for thermostability assays. 
 
Affinity purification of DDM or DIBMALP TS-SNAP-β2AR 
Solubilised DDM-TS-SNAP-β2AR and DIBMALP- β2AR samples were purified using 
20μL of 5% MagStrep “type3” XT magnetic beads suspension (IBA). Beads were 











solubilisation buffers before resuspension in samples. Samples were incubated with 
beads for 2hrs at 80RPM on a roller in cold room. Supernatant was then removed from 
beads using magnetic rack and beads were washed twice with wash buffer (20mM 
HEPES, 10% glycerol, 150mM NaCl, pH 7.5 with 0.1% DDM for DDM sample only), 
before resuspension in 50μL elution buffer. Elution buffer consisted of 1part 10X buffer 
BXT (IBA) and 9 parts wash buffer. Elution took place for 2 hours at 80RPM on a roller 
in cold room. Sample were then separated from beads using magnetic rack. 
 
Fluorescence size exclusion chromatography (FSEC) 
30μL crude lysate samples of Alexa488-DDM or DIBMALP-β2AR were run of Yarra 
1.8μm SEC-x300 2.5mL column (Phenomenex, CA, US) using shimadzu prominence 
HPLC system. Running buffer consisted of 20mM HEPEs, 150mM NaCl, 5% glycerol, 
and 0.03% DDM for DDM- β2AR sample only. FSEC took place at a flow rate of 
0.2mL/min and 0.2mL fractions collected. Samples were excited at 488nm, and 
emission collected at 520nm. GE HMW calibration kit was use as the standard.  
 
In gel fluorescence  
15μL of each FSEC fraction was run on TruPageTM 4-20% Bis-Tris 17 well gel using 
NuPageTM LDS sample loading buffer with 5mM Dithiothreitol (DTT) and NuPageTM 
MOPs running buffer. Gels were run for 50min at 200V. Samples were not boiled prior 
to gel electrophoresis. 5μL PageRulerTM Prestained Protein Ladder (10-140kDa).  was 
used as the ladder. Gels were scanned on GE Typhoon scanner using Fluorstage and 
Cy2 or Cy5 filter sets. PMT was set to auto and pixel size to 200μm. 
 
TR-FRET ligand binding assays 
TR-FRET between the donor Lumi4-Tb and the fluorescent acceptors 633/650 S-
propranolol-red (CellAura, UK, supplied by Hello Bio, UK, cat no. HB7817) (F-
propranolol) was measured by exciting at 337nm and quantifying emission at 665nm 
and 620nm using a PheraStar FSX (BMG Labtech) and HTRF 337 665/620 module 
(BMG Labtech). Assay buffer consisted of 20mM HEPES, 5% glycerol, 150mM NaCl, 
and 0.5% Bovine Serum Albumin (BSA), pH 8.0 for DDM solubilised samples 0.1% 
DDM was used. All binding assays used a final concentration of 1% Dimethyl sulfoxide 
(DMSO), assay volume of 30µL, 384 well OptiPlates (PerkinElmer, US) and 3µM 
cyanopindolol was used to determine non-specific binding (NSB). Receptors were 
added to plates last, and the plates were incubated at room temperature for 45 mins 
prior to reading. For competition binding assays 100nM of F-propranolol was used for 
membrane and DDM samples and 200nM F-propranolol for DIBMA samples. 
 
 
ThermoFRET thermostability assays 
Solubilised Lumi4-Tb labelled β2AR was incubated with 10μM BODIPY™ FL L-
Cystine dye (Molecular Probes, U.S) with or without 200nM F-propranolol or 100μM 
cyanopindolol, for 15 mins on ice in 20mM HEPES, 150mM NaCl, 5% glycerol, 0.5% 
BSA, pH8. For DDM samples 0.1% DDM was used. 20μL samples were added to 
each well of a 96-well PCR plate and incubated for 30 min over a temperature gradient 
of 20-78°C across the plate using alpha cycler 2 PCR machine (PCRmax, U.K). 
Samples were transferred to a 384-well proxiplate (PerkinElmer, U.S). TR-FRET 
between BODIPY™ FL L-Cystine dye and Lumi4-Tb was read by exciting at 337nm 











module (BMG Labtech). F-propranolol and fluorescent XAC (F-XAC) (CellAura, UK) 
binding was measured using HTRF 337 665/620 module as above. 
 
 
Data analysis  
TR-FRET ligand binding data 
Total and NSB for F-propranolol binding to the β2AR was fitted to one-site models in 
GraphPad Prism 8 according to equations 1 and 2. 
 
𝑇𝑜𝑡𝑎𝑙 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 =  ⌈
𝐵𝑚𝑎𝑥 ∗ 𝑋 
(𝐾𝑑 + 𝑋)
⌉ + [𝑁𝑆 ∗ 𝑋 + 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑] 
 
                                                                                                                                                  
Equation 1 
Where: 
NS = slope of linear nonspecific binding 
Background = Y when X is 0 
Bmax = the maximum specific binding  
Kd = the equilibrium dissociation constant 
Y = specific binding  
X= concentration of tracer 
 
𝑁𝑆𝐵 =  [𝑁𝑆 ∗ 𝑋 + 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑] 
                        
Equation 2 
 
Specific binding of F-propranolol to the β2AR was fitted to the one site specific binding 
model in GraphPad Prism 8 according to equation 3. Final Kd values were taken as an 
average of Kd values from individual specific curve fits. 
 
𝒀 =  
𝐵𝑚𝑎𝑥 ∗ 𝑋 
(𝐾𝑑 + 𝑋)
 
                                                                                                                                                  
Equation 3 
Where: 
Y = specific binding  
Kd = the equilibrium dissociation constant of the labelled ligand 
 
Equilibrium competition binding data was fitted to the One site Fit Ki model in 
GraphPad Prism 8 according to equation 4 and 5. Final Ki values were taken as an 
average of individual curve fits. 
 
𝑌 =  
(𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚)
(1 + 10(𝑥−𝐿𝑜𝑔𝐼𝐶50 )) + 𝐵𝑜𝑡𝑡𝑜𝑚
  
 
                                             
Equation 4 
Where: 





















                                                                                                                                                  
Equation 5 
Where: 
Ki = the inhibition constant of the unlabelled ligand 
[L] = concentration of labelled ligand 
Kd = the equilibrium dissociation constant of the labelled ligand. 
 
ThermoFRET thermostability curves 
All ThermoFRET thermostability data from each experiment was fitted to a Boltzmann 
sigmoidal curve using GraphPad Prism 8 according to equation 6 to obtain a melting 
temperature (Tm) value. Final Tm values were taken as an average of Tm values from 
individual curve fits. 
 
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +  
(𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚)





                                                                                                                                                  
Equation 6 
Where: 
Y = the relative concentration of proteins in the unfolded state 
X = Temperature (oC) 




Quantification and statistical analysis 
Comparison of Tm, Kd or Ki values was made using a one-way Analysis Of Variance 
(ANOVA) test and Tukey’s post hoc multiple comparison test. Statistical comparison 
of Tm values obtained with F-propranolol Vs BODIPY™ FL L-Cystine dye was made 
using an unpaired t test. All statistical analysis was completed in GraphPad Prism 8 
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Table 1: Ligand binding parameters to different preparations of β2AR.   
Note: values shown are mean of n=3 individually fitted curves ±SEM, as determined 





Table 2. Thermal stability of different preparations of β2AR.  
Note: reported error values are SEM 
aβ2AR thermostability was measured using F-propranolol dissociation 




Membranes DDM DIBMA 


























































 Tm (oC) 
ThermoFRET   
Tm(oC) 
F-ligand 
Membrane β2AR 62.4±0.2 - 
Membrane β2AR + F-propranolol 61.6±0.4 60.1±0.6 a 
Membrane β2AR + cyanopindolol 63.0±0.4 - 
DDM β2AR 35.2±2.4 - 
DDM β2AR + F-propranolol 37.8 ±0.4 36.0 ±0.6a 
DDM β2AR + cyanopindolol 41.9 ±0.1 - 
DIBMALP β2AR - 46.8 ±2.1a 












Figure titles and legends 
 
Figure 1: Solubilisation of β2AR from the mammalian cell membrane using DDM 
and DIBMA. A) Representative in gel fluorescence (cy5) of purified DDM-β2AR and 
DIBMALP-β2AR B) Solubilisation of DDM Vs DIBMA, Alexa488 labelled β2AR was 
quantified and percentage of membrane calculated (n=3 ± SEM). C) FSEC analysis 
of DDM- β2AR and DIBMA-β2AR samples using Yarra X300 column (Mean of n=3).   
 
Figure 2: A comparision of F-propranolol binding to β2AR in membranes, DDM 
and DIBMALPs. A-C) Representative F-propranolol (2-666nM) equilibrium saturation 
plots showing total and non-specific binding to the 2AR in (A) HEK cell membranes, 
(B) DDM and (C) DIBMALPs, n=1. D-F) Saturation binding curves showing specific 
binding and associated affinity (pKd) values for F-propranolol binding to the 2AR in 
(D) HEK cell membranes, (E) DDM and (F) DIBMALPs, curves show combined 
normalised data mean ± SEM, n=3.  
Figure 3: Competition TR-FRET ligand binding studies using F-propranolol as a 
tracer and unlabelled propranolol, ICI 118,551 and isoprenaline as competitors. A) 
β2AR membranes, B) DDM-β2AR C) DIBMALP- β2AR, curves show normalized 
combined data of n=3, error bars show ± SEM.  
 
Figure 4: ThermoFRET thermostability curves in A) β2AR membranes B) DDM 
solubilised β2AR C) DIBMALP-β2AR in the presence and absence of cyanopindolol 
(100M) and F-propranolol (200nM). D) β2AR and A2AR TR-FRET thermostability 
curves obtained by measuring reduction in fluorescent F-propranolol (200nM) and F-
XAC (200nM) binding. All curves show normalized combined data, data points show 































































































































































































































































































































































β2AR  + F-propanolol






























































































Please upload a single Word document that includes up to four Highlights. Each 
highlight can be no more than 89 characters, including spaces 
 
 
 DIBMA can be used to extract the human β2AR from mammalian cells 
 DIBMALP-β2AR retains ligand binding ability and shows improved stability 
 Our novel TR-FRET based ligand binding methods removed the need for purification 
for DIBMALP-β2AR characterisation 
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